Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
3 Research Methodology
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Share Analysis
3.4 Trade Analysis
3.5 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Emergence of digital health technologies in mental health
(Impact weightage-45%) 22
4.2.2 Growing prevalence of mental disorders around the globe
(Impact weightage-30%) 23
4.2.3 New focus areas in the care continuum are prevention and recovery
(Impact weightage-25%) 24
4.3 Restraints
4.3.1 Low public awareness of mental disorders and treatments in emerging nations (Impact weightage-55%)
4.3.2 Cultural Stigma preventing the market growth (Impact weightage-45%)
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis


6 Global Depression Screening Market, By Disease Type
6.1 Introduction
6.2 Anxiety
6.3 Mood Disorders
6.4 Depression
6.5 Bipolar Disorders
6.6 Psychotic Disorders
6.7 Eating Disorders
7 Global Depression Screening Market, By Diagnosis
7.1 Introduction
7.2 Psychological Test
7.3 Lab Tests
7.4 Depression Screening Tests
8 Global Depression Screening Market, By Treatment
8.1 Introduction
8.2 Medication
8.3 Brain-Stimulation Treatments
8.4 Substance Abuse Treatment
9 Global Depression Screening Market, By End User
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Medical Research Centers
9.4 Academic Institutes
10 Global Depression Screening Market, By Region
10.1 Introduction
10.2 Americas
10.2.1 U.S.
10.2.2 Canada
10.2.3 South America
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Western Europe
10.3.7 Eastern Europe


10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
11 Company Share Analysis
12 Company Profiles: Top 7 Players
12.1 Allergan
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Products
12.1.4 Strategy
12.1.5 Key Developments
12.2 Eli Lilly
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Products
12.2.4 Strategy
12.2.5 Key Developments
12.3 Novartis AG.
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Products
12.3.4 Strategy
12.3.5 Key Developments
12.4 Alkermes
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Products
12.4.4 Strategy
12.4.5 Key Developments
12.5 Bristol-Myers Squibb Company
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Products
12.5.4 Strategy
12.5.5 Key Developments
12.6 Pfizer
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Products
12.6.4 Strategy
12.6.5 Key Developments